FindTrial
Sign In

Evaluating the efficacy and safety of intralesional triamcinolone acetonide injections plus tacrolimus ointment combination therapy in vitiligo patients.

Evaluating the efficacy and safety of intralesional triamcinolone acetonide injections plus tacrolimus ointment combination therapy in vitiligo patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018162
Enrollment
Unknown
Registered
2018-09-03
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Case series:intralesional triamcinolone acetonide injection

Sponsors

Shanghai 6th People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Vitiligo patients with distal limb skin lesions have not receive any systemic or local treatments for vitiligo 1 month before enrollment; (2) Patients are informed and accept this curative effect observation.

Exclusion criteria

Exclusion criteria: Anaphylaxis to tacrolimus ointment, triamcinolone acetonide injection and its components; severe or uncontrolled chronic liver, kidney, heart, blood diseases, diabetes, osteoporosis and lung diseases; history of malignant tumors; systematic use of immunosuppressive agents or glucocorticoids for other diseases; pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
dermatoscope;—

Countries

China

Contacts

Public ContactWANG XIAOMING

Shanghai 6th People's Hospital

wxmdaobao104@163.com+86 13818668160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026